The UK's political climate will dominate market narratives, with the 10-year Treasury yield down 3 basis points to 4.773%.

Reuters, October 6 – Pharmaceutical distributor McKesson (MCK.N) and private equity firm Clayton Dubilier & Rice (CD&R) reached an agreement on Tuesday to take infusion therapy provider Option Care Health (OPCH.O) private, in a deal valued at approximately $5.8 billions, including debt. The acquisition offer of $32.05 per share represents a 37.1% premium over Option Care's most recent closing price. As a US pharmaceutical distributor, McKesson is seeking to expand its healthcare services portfolio, and this transaction marks its latest move. It also follows the private equity fund’s previous acquisition of another home health service provider, Enhabit. Option Care Health is the largest independent provider of infusion therapy services in the US, serving over 308,000 patients annually through more than 197 service centers, offering home and outpatient infusions, specialty pharmacy, and care for complex conditions. With an aging population and a growing number of patients choosing care outside costly hospital settings, demand for home healthcare in the US continues to increase. Upon closing, CD&R will hold the majority stake, while McKesson will retain a minority interest. Option Care Health will continue to operate as an independent company led by its existing management team. As per transaction terms, McKesson will invest about $1.4 billions to acquire a 49% stake, with the right to acquire CD&R's remaining 51% interest at a later date. According to Michael Cherny, an analyst at Leerink Partners, this deal positions McKesson in line with the trend of healthcare services shifting away from hospitals and medical institutions to alternative sites of care. Additionally, given McKesson’s current operation of Canada’s leading infusion and injection network, Inviva, the transaction extends its reach in the US home infusion market. McKesson’s oncology and multi-specialty business segments, including infusion services, posted revenues of $14.2 billions in the most recent quarter, up 33% year-over-year, benefiting from specialty drug distribution and contributions from acquisitions. The deal is expected to close in the first half of 2027, after which Option Care Health will become a private company.

The Bank of England hawkish official Mann stated that the labor market is "static" rather than loose, and warned that inflation is deeply entrenched; rising fuel and energy prices may cause inflation to "significantly exceed 4%" early next year.

October 6 - Semiconductor product manufacturer Diodes (DIOD.O) saw its stock price rise 3.38% in pre-market trading to $107.64. BofA has initiated coverage of DIOD with a “Buy” rating and a price target of $135, implying about 30% upside from the previous closing price. According to the report, DIOD holds a favorable position in the automotive, industrial, and AI data center semiconductor markets, positioning it to expand its market share. The increasing use of semiconductors in automobiles and growing demand for AI infrastructure are expected to drive the company’s long-term growth. The firm anticipates that DIOD’s AI data center business—which currently accounts for about 12% of total revenue—could triple by 2030. As of the previous trading day’s close, the stock’s year-to-date growth has already more than doubled. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. Automated translations may contain errors or lack context and are provided solely for the convenience of readers. Reuters accepts no liability for any damages or losses resulting from the use of automated translation features.)

On October 6th, shares of pharmaceutical company BridgeBio Pharma (BBIO.O) rose 2.5% in pre-market trading to $67.80. The company announced that the U.S. Food and Drug Administration (FDA) has granted priority review to its application seeking approval for the investigational oral drug infigratinib for the treatment of children with achondroplasia, the most common type of dwarfism. The FDA has set a target decision date of February 4, 2027. The application is based on a late-stage clinical trial that met both primary and key secondary endpoints; children treated with infigratinib experienced an adjusted annual growth velocity 1.74 centimeters greater than those given placebo. The drug also improved arm span and body proportions in children under eight years old. No serious adverse events or discontinuations related to the drug were reported. BridgeBio plans to apply for European approval in the fourth quarter of 2026. As of the close of the previous trading day, BBIO shares are down 13.5% year-to-date. (For the convenience of non-English speakers, Reuters has automated this report into several other languages. Because automated translation may contain errors or lack required context, Reuters does not guarantee the accuracy of automated translation, which is provided for readers’ convenience only. Reuters accepts no liability for any damages or losses arising from the use of automated translation.)